The testing program could be extended for several reasons.
I also doubt that results were negative. Negative results would not make a delay necessary.
1,
Results are as expected or better.
This would explain the secrecy and partners are busy wrapping up the legalities to hit the next step of production engineering as stated in the AGM presentation.
To enter this stage several steps between partners must be arranged before announcement can be made as this identifies the commericalisation onset of the whole testing procedure.
2,
Results were not excactly what expected and OBJ needs to go back to the drawing board to increase efficiency or consumer related design.
I find this not very likely as one of the key advantages of our technology are the simplicity and cheap production costs.
3,
testing takes longer as it involves pharmaceutical testing cycles with an outlook onto practical paths in the healthcare market.
When one is convinced to be onto a winner one tests usually longer periods to make sure that there are no surprises.
In general, the secrecy of the testing regime with this FMCG is usually a sign of a breakthrough point in development.
There will, in all likelihood, no indication of the outcome whatsoever until news hit.
- Forums
- ASX - By Stock
- WFL
- the original fmcg company deal
the original fmcg company deal, page-12
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add WFL (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.478M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
WFL (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online